| Project/Area Number |
15K09020
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
WANG TING 岩手医科大学, 医学部, 助教 (70416171)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Takikawa Yasuhiro 岩手医科大学, 医学部, 教授 (50254751)
Miyasaka Akio 岩手医科大学, 医学部, 准教授 (80382597)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | TGF-β / IFN/5-FU 併用療法 / HCC / IFNα-2b / 5-FU / ERK1/2 / E-cadherin / Claudin-1 / 浸潤性肝癌 / 化学併用療法 / TGFβ |
|---|
| Outline of Final Research Achievements |
Experimental Study: 5-FU increased both the expression and secretion levels of TGF-β1 in hepatoma cells, but not in normal hepatocytes. 5-FU inhibited TGF-β-mediated apoptosis signaling but stimulated TGF-β-mediated EMT signaling via ERK1/2. On the other hand, IFNα-2b can antagonize the effects of 5-FU on TGF-β expression and TGF-β-mediated signaling.
Clinical study: The serum levels of TGF-β1 prior to the therapy were significantly decreased after the combination therapy. However, in cases with a HCV background, although the serum levels of TGF-β decreased after the combination therapy in all the patients, 41.2% of the cases responded poorly to the therapy with a continued worsening of their condition, and there were no significant differences in TGF-β levels between patients who worsened and improved.
|
